Role of E6 and E7 oncoproteins anogenital malignancies

Seminars in Virology

Volumn 7, Issue 5, 1996, Pages 295-304

  Kubbutat, Michael H G ^a   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

E6; E7; HPV induced malignancies; Viral oncoproteins

Indexed keywords

CELL PROTEIN; ONCOPROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS DNA; VIRUS PROTEIN;

CARCINOGENESIS; CELL CYCLE S PHASE; GENITAL TRACT CANCER; GENOME; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

CANCER VIRUS; DNA VIRUSES; HUMAN PAPILLOMA VIRUS; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0030267239     PISSN: 10445773     EISSN: None     Source Type: Journal    
DOI: 10.1006/smvy.1996.0037     Document Type: Review

References (113)

1. 1. Parkin DM, Laara E, Muir CS (1988) Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41:184-197
2. 2. zur Hausen H (1991) Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13
3. 3. Chan SY, Delius H, Halpern AL, Bernard HU (1995) Analysis of genomic sequences of 95 papillomavirus types - uniting typing, phylogeny, and taxonomy. J Virol 69:3074-3083
4. 4. Cullen AP, Reid R, Campion M, Lorincz AT (1991) Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 65:606-612
5. 5. Matsukura T, Koi S, Sugase M (1989) Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 172:63-72
6. 6. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H (1985) Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114
7. 7. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PGd, Durst M, Gissmann L, Roman A, Turek LP (1987) Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis. EMBO J 6:3745-3753
8. 8. Jeon S, Lambert PF (1995) Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 92:1654-1658
9. 9. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT (1989) HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratin ocytes. EMBO J 8:3905-3910
10. 10. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratin ocytes. J Virol 63:4417-4421
11. 11. Hudson JB, Bedell MA, McCance DJ, Laiminis LA (1990) Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64:519-526
12. 12. zur Hausen H (1991) Viruses in human cancer. Science 254:1167-1172
13. 13. Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79
14. 14. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937
15. 15. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsilio E, Paucha E, Livingston DM (1988) SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283
16. 16. Whyte P, Williamson NM, Harlow E (1989) Cellular targets for transformation by the adenovirus E1A proteins. Cell 56:67-75
17. 17. Lane DP, Crawford LV (1979) T-antigen is bound to host protein in SV40-transformed cells. Nature 278:261-263
18. 18. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH (1990) The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 9:153-160
19. 19. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM (1989) Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8:4099-4105
20. 20. Ciccolini F, Di Pasquale G, Carlotti F, Crawford L, Tommasino M (1994) Functional studies of E7 proteins from different HPV types. Oncogene 9:2633-2638
21. 21. McIntyre MC, Ruesch MN, Laimins LA (1996) Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 215:73-82
22. 22. Davies R, Hicks R, Crook T, Morris J, Vousden KH (1993) Human papillomavirus type 16 E7 associates with a histone H 1 kinase and with p107 through sequences necessary for transformation. J Virol 67:2521-2528
23. 23. Tommasino M, Adamczewski JP, Carlotti F, Barth CF, Manetti R, Contorni M, Cavalieri F, Hunt T, Crawford L (1993) HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 8:195-202
24. 24. Antinore MJ, Birrer MJ, Patel D, Nader L, McCance DJ (1996) The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J 15:1950-1960
25. 25. Liu F, Green MR (1994) Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains. Nature 368:520-525
26. 26. Zwerschke W, Joswig S, Jansen Durr P (1996) Identification of domains required for transcriptional activation and protein dimerization in the human papillomavirus type-16 E7 protein. Oncogene 12:213-220
27. 27. Massimi P, Pim D, Storey A, Banks L (1996) HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 12:2325-2330
28. 28. Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM (1992) Structure - function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66:2418-2427
29. 29. Watanabe S, Kanda T, Sato H, Furuno A, Yoshiike K (1990) Mutational analysis of human papillomavirus type 16 E7 functions. J Virol 64:207-214
30. 30. Edmonds C, Vousden KH (1989) A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol 63:2650-2656
31. 31. McIntyre MC, Frattini MG, Grossman SR, Laimins LA (1993) Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol 67:3142-3150
32. 32. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21
33. 33. Hochstrasser M (1995) Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7:215-223
34. 34. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136
35. 35. Huibregtse JM, Scheffner M, Howley PM (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10:4129-4135
36. 36. Huibregtse JM, Scheffner M, Howley PM (1993) Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 13:775-784
37. 37. Rolfe M, Beer Romero P, Glass S, Eckstein J, Berdo I, Theodoras A, Pagano M, Draetta G (1995) Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc Natl Acad Sci USA 92:3264-3268
38. 38. Scheffner M, Nuber U, Huibregtse JM (1995) Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373:81-83
39. 39. Scheffner M, Huibregtse JM, Howley PM (1994) Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci USA 91:8797-8801
40. 40. Ciechanover A, Shkedy D, Oren M, Bercovich B (1994) Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. J Biol Chem 269:9582-9589
41. 41. Nuber U, Schwarz S, Kaiser P, Schneider R, Scheffner M (1996) Cloning of human ubiquitin-conjugating enzymes Ubch6 and Ubch7 (E2-F1) and characterization of their interaction with E6-Ap and Rsp5. J Biol Chem 271:2795-2800
42. 42. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505
43. 43. Huibregtse JM, Scheffner M, Howley PM (1993) Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 13:4918-4927
44. 44. Crook T, Tidy JA, Vousden KH (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556
45. 45. Dalal S, Gao QS, Androphy EJ, Band V (1996) Mutational analysis of human papillomavirus type-16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial-cells. J Virol 70:683-688
46. 46. Pim D, Storey A, Thomas M, Massimi P, Banks L (1994) Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 9:1869-1876
47. 47. Lechner MS, Laimins LA (1994) Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68:4262-4273
48. 48. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM (1994) High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265:386-391
49. 49. Friedman PN, Chen X, Bargonetti J, Prives C (1993) The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci USA 90:3319-3323
50. 50. Marston NJ, Jenkins JR, Vousden KH (1995) Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10:1709-1715
51. 51. Mansur CP, Marcus B, Dalal S, Androphy EJ (1995) The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10:457-465
52. 52. Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM (1992) Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol 66:5100-5105
53. 53. Medcalf EA, Milner J (1993) Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene 8:2847-2851
54. 54. Marston NJ, Crook T, Vousden KH (1994) Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9:2707-2716
55. 55. Chen JJ, Reid CE, Band V, Androphy EJ (1995) Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 269:529-531
56. 56. Weis K, Griffiths G, Lamond AI (1994) The endoplasmic reticulum calcium-binding protein of 55kDa is a novel EF-hand protein retained in the endoplasmic reticulum by a carboxyl-terminal His-Asp-Glu-Leu motif. J Biol Chem 269:19142-19150
57. 57. Klingelhutz AJ, Foster SA, McDougall JK (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380:79-82
58. 58. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015
59. 59. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, Schiller JT (1991) The full-length E6 protein of human papillomavirus type 16 has transforming and transactivating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 65:4860-4866
60. 60. Storey A, Banks L (1993) Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene 8:919-924
61. 61. Nakagawa S, Watanabe S, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T (1995) Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 212:535-542
62. 62. Goodrich DW, Lee WH (1993) Molecular characterization of the retinoblastoma susceptibility gene. Biochim Biophys Acta 1155:43-61
63. 63. Whyte P (1995) The retinoblastoma protein and its relatives. Semin Cancer Biol 6:83-90
64. 64. Suzuki Takahashi I, Kitagawa M, Saijo M, Higashi H, Ogino H, Matsumoto H, Taya Y, Nishimura S, Okuyama A (1995) The interactions of E2F with pRB and with p107 are regulated via the phosphorylation of pRB and p107 by a cyclin-dependent kinase. Oncogene 10:1691-1698
65. 65. Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin WG, Jr (1995) The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol 15:742-755
66. 66. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
67. 67. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
68. 68. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
69. 69. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) Waf1, a potential mediator of p53 tumor suppression. Cell 75:817-825
70. 70. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace A, Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597
71. 71. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299
72. 72. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468
73. 73. Okamoto K, Beach D (1994) Cyclin G is a transcriptional target of the p53 tumor suppression protein. EMBO J 13:4816-4822
74. 74. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649
75. 75. Crook T, Marston NJ, Sara EA, Vousden KH (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817-827
76. 76. Pietenpol JA, Tokino T, Thiagaligam S, El-Deiry W, Kinzler KW, Vogelstein B (1994) Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91:1998-2002
77. 77. White E (1996) Life, death, and the pursuit of apoptosis. Genes Dev 10:1-15
78. 78. Knudson MC, Tung KSK, Tourtellotte WG, Brown GAJ, Korsmeyer SJ (1995) Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-98
79. 79. Caelles C, Helmberg A, Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220-223
80. 80. Wagner AJ, Kokontis JM, Hay N (1994) Mye-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/ cip1. Genes Dev 8:2817-2830
81. 81. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9:2170-2183
82. 82. Phelps WC, Bagchi S, Barnes JA, Raychaudhuri P, Kraus V, Munger K, Howley PM, Nevins JR (1991) Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism. J Virol 65:6922-6930
83. 83. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR (1992) Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89:4549-4553
84. 84. Morris JDH, Crook T, Bandara LR, Davies R, LaThangue NB, Vousden KH (1993) Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene 8:893-898
85. 85. Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, Garsky VM, Oliff A, Heimbrook DC (1993) Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol 13:953-960
86. 86. Degregori J, Leone G, Ohtani K, Miron A, Nevins JR (1995) E2F-1 Accumulation bypasses a G(1) arrest resulting from the inhibition of G(1) cyclin-dependent kinase-activity. Gene Dev 9:2873-2887
87. 87. Hickman ES, Picksley SM, Vousden KH (1993) Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9:2177-2181
88. 88. Demers GW, Foster SA, Halbert CL, Galloway DA (1994) Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA 91:4382-4386
89. 89. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR (1994) p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 91:5320-5324
90. 90. Zerfass K, Levy LM, Cremonesi C, Ciccolini F, Jansendurr P, Crawford L, Ralston R, Tommasino M (1995) Cell Cycle-Dependent Disruption of E2F-P107 Complexes by Human Papillomavirus Type-16 E7. J Gen Virol 76:1815-1820
91. 91. Lam EW-F, Morris JDH, Davies R, Crook T, Watson RJ, Vousden K (1994) HPV16 E7 oncoprotein deregulates E-myb expression: correlation with targeting of p107/ E2F complexes. EMBO J 13:871-878
92. 92. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA (1996) Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12:1173-1180
93. 93. Zerfass K, Schulze A, Spitkovsky D, Friedman V, Henglein B, Jansen Durr P (1995) Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol 69:6389-6399
94. 94. Arroyo M, Bagchi S, Raychaudhuri P (1993) Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol Cell Biol 13:6537-6546
95. 95. Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML (1996) Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells. Nature 380:262-265
96. 96. Crook T, Vousden KH (1992) Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 11:3935-3940
97. 97. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH (1992) Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 339:1070-1073
98. 98. Wrede D, Tidy JA, Crook T, Lane D, Vousden KH (1991) Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinogen 4:171-175
99. 99. Scheffner M, Munger K, Byrne JC, Howley PM (1991) The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88:5523-5527
100. 100. Hubbert NL, Sedman SA, Schiller JT (1992) Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 66:6237-6241
101. 101. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA (1992) Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 11:3045-3052
102. 102. Inoue H, Kondoh G, Sudiro TM, Hakura A (1992) Stability of p53 protein in rat cells transformed by various viral transforming genes. Virology 187:343-347
103. 103. Crook T, Fisher C, Masterson PJ, Vousden KH (1994) Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9:1225-1230
104. 104. Gu Z, Pim D, Labrecque S, Banks L, Matlashewski G (1994) DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene 9:629-633
105. 105. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR (1993) Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90:3988-3992
106. 106. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A, Hoppe-Seyler F (1995) Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10:927-936
107. 107. Thomas M, Massimi P, Jenkins J, Banks L (1995) HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 10:261-268
108. 108. Wu X, Levine AJ (1994) p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91:3602-3606
109. 109. Pan H, Griep AE (1994) Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 8:1285-1299
110. 110. von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L (1988) Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 48:3780-3786
111. 111. Steele C, Sacks PG, Adler Storthz K, Shillitoe EJ (1992) Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. Cancer Res 52:4706-4711
112. 112. Steele C, Cowsert LM, Shillitoe EJ (1993) Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res 53:2330-2337
113. 113. Tan TM, Ting RC (1995) In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res 55:4599-4605